About: Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19
Creator	Wang, Yi Chen, Ting Li, Huan Li, Sha Li, H Chen, H Wang, Xiong Fu, Xiaoying Zhu, X Li, Ting Wang, L Wang, X Wang, Y Chen, Yi Chen, T Han, Huan Chen, Chen, Mei Chen, S Li, S Wang, Chen, Hai Chen, Shaojin Han, L Han, Limei He, Lvfen Wang, Licheng Wang, Xiaoxia Xing, Mei Zhu, Xiong Fu, X Zhu, Yi Wang, Limei Xing, Hai Xing, M Zhu, Xiaoxia
source	Elsevier; Medline; PMC
abstract	The ongoing global pandemic (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a huge public health issue. Hence, we devised a multiplex reverse transcription loop-mediated isothermal amplification (mRT-LAMP) coupled with a nanoparticle-based lateral flow biosensor (LFB) assay (mRT-LAMP-LFB) for diagnosing COVID-19. Using two LAMP primer sets, the ORF1ab (opening reading frame 1a/b) and N (nucleoprotein) genes of SARS-CoV-2 were simultaneously amplified in a single-tube reaction, and detected with the diagnosis results easily interpreted by LFB. In presence of FITC (fluorescein)-/digoxin- and biotin-labeled primers, mRT-LAMP produced numerous FITC-/digoxin- and biotin-attached duplex amplicons, which were determined by LFB through immunoreactions (FITC/digoxin on the duplex and anti-FITC/digoxin on the test line of LFB) and biotin/treptavidin interaction (biotin on the duplex and strptavidin on the polymerase nanoparticle). The accumulation of nanoparticles leaded a characteristic crimson band, enabling multiplex analysis of ORF1ab and N gene without instrumentation. The limit of detection (LoD) of COVID-19 mRT-LAMP-LFB was 12 copies (for each detection target) per reaction, and no cross-reactivity was generated from non-SARS-CoV-2 templates. The analytical sensitivity of SARS-CoV-2 was 100% (33/33 oropharynx swab samples collected from COVID-19 patients), and the assay's specificity was also 100% (96/96 oropharynx swab samples collected from non-COVID-19 patients). The total diagnostic test can be completed within 1 h from sample collection to result interpretation. In sum, the COVID-19 mRT-LAMP-LFB assay is a promising tool for diagnosing SARS-CoV-2 infections in frontline public health field and clinical laboratories, especially from resource-poor regions.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1016/j.bios.2020.112437
bibo:pmid	32692666
has license	no-cc
sha1sum (hex)	6d3dbf549db45defaad4114f9720c23a3e1e6937
schema:url	https://doi.org/10.1016/j.bios.2020.112437
resource representing a document's title	Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19
has PubMed Central identifier	PMC7361114
has PubMed identifier	32692666
schema:publication	Biosens Bioelectron
resource representing a document's body	covid:6d3dbf549db45defaad4114f9720c23a3e1e6937#body_text
is schema:about of	named entity 'Statement' named entity 'biosensor' named entity 'nanoparticle' named entity 'hapten' named entity 'current COVID-19 outbreak' named entity 'rRT-PCR' named entity 'COVID-19' named entity 'SYBR' named entity 'polymerase' named entity 'stem-loop' named entity 'SARS-CoV-2' named entity 'Shanghai' named entity 'plasmid' named entity 'clinical symptoms' named entity 'COVID-19' named entity 'amplicons' named entity 'cross-reaction' named entity 'FITC' named entity 'China' named entity 'reverse transcription' named entity 'World Health Organization' named entity 'SARS-CoV-2' named entity 'coronavirus' named entity 'COVID-19' named entity 'PBS' named entity 'COVID-19' named entity '5' end' named entity 'SARS-CoV-2' named entity 'nucleotide' named entity 'global health' named entity 'negative result' named entity 'biotin' named entity 'biotin' named entity 'hapten' named entity 'TL1' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'Wuhan' named entity 'plasmid' named entity 'Hubei province, China' named entity 'COVID-19' named entity 'epidemic' named entity 'fungi' named entity 'reaction time' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'sample pad'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software